Cellumed and ARTES Sign Development and License Agreement
Accelerate development of GMP-grade production enzymes essential for manufacturing mRNA-based biopharmaceuticals
(PresseBox) - Today, Cellumed Co. Ltd., listed stock market company and Germany based ARTES Biotechnology GmbH announce the execution of a Development and License Agreement aiming at the generation of microbial production cell lines, processes and documentation for the cGMP manufacturing of two enzymes required in the manufacturing process of mRNA vaccines.
Under this agreement, ARTES shall be responsible for the development of high yield microbial cell lines expressing two recombinant enzymes. Further steps at ARTES will include the development of up- and downstream processes as well as of the analytical assays to characterize the two products. Results will be transferred by ARTES to its German CMO partner Richter-Helm BioLogics GmbH & Co. KG for subsequent cGMP production. The project management will be supported by ARTES´ Korean representative Quality by Design, Inc.
Cellumed predicts that the mRNA platform will gradually expand product development in the future as a base technology with high potential for developing other vaccines and therapeutics even after COVID-19 subsides. Therefore, Cellumed will realize technological independence of materials through the localization of production enzymes, which are key raw materials for mRNA vaccines. In addition, it is planning to supply production enzymes in Korea first, and is also planning to gradually advance into the global market.
Statement of Dr. Michael Piontek, Managing Director of ARTES Biotechnology: “We are very proud being chosen by Cellumed for this important task of supporting the establishment of most up-to-date mRNA technology in South-Korea. We will contribute our long term experience in recombinant biotechnology and will give all our outstanding expertise and know-how in this collaboration. We are looking forward to building a strong and long lasting relation with Cellumed.”
ARTES Biotechnology GmbH is a Germany-based company specialized in recombinant protein production, process and vaccine (VLP-based) development from microbial expression systems. ARTES offers generation of optimized production cell lines in proprietary yeast expression systems based on Hansenula polymorpha. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld.
www.artes-biotechnology.com
Unternehmensinformation / Kurzprofil:
ARTES Biotechnology GmbH is a Germany-based company specialized in recombinant protein production, process and vaccine (VLP-based) development from microbial expression systems. ARTES offers generation of optimized production cell lines in proprietary yeast expression systems based on Hansenula polymorpha. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld.
www.artes-biotechnology.com
Datum: 13.10.2021 - 14:39 Uhr
Sprache: Deutsch
News-ID 649138
Anzahl Zeichen: 2730
contact information:
Town:
Langenfeld
Kategorie:
Handcrafts
Diese Pressemitteilung wurde bisher 390 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cellumed and ARTES Sign Development and License Agreement"
steht unter der journalistisch-redaktionellen Verantwortung von
ARTES Biotechnology GmbH (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
